Back to search
FDAFDA · Food and drugs·Recall number D-0318-2023

TPN (a) 100GM/AA, 285GM/DEX, (b)55GM/LIP 2300ML, (c)55GM/AA 285GM/DEX 50GM/LIP1800ML, (d)TPN AA:100GM DEX:250GM LIP:50GM 2400ML, (e) 55GM DEX:285GM 1800ML, Rx Only, use with Curlin pump or no pump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320

Published February 22, 2023 · Recall initiated: December 27, 2022

Summary

FDA records drug Class II recall D-0318-2023, published February 22, 2023 and initiated December 27, 2022. Recalling firm: Sentara Infusion Services; Status: Terminated; Reported quantity: 26 bags; Lot: Beyond Use Date: December 24-3 , 2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of sterility assurance

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sentara Infusion Services
Distributor
Dispensed to Patients Nationwide.
Lot
Beyond Use Date: December 24-3 , 2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TPN (a) 100GM/AA, 285GM/DEX, (b)55GM/LIP 2300ML, (c)55GM/AA 285GM/DEX 50GM/LIP1800ML, (d)TPN AA:100GM DEX:250GM LIP:50GM 2400ML, (e) 55GM DEX:285GM 1800ML, Rx Only, use with Curlin pump or no pump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320 recalled?

Yes. FDA published recall D-0318-2023 on February 22, 2023. Reported hazard: Lack of sterility assurance

What should I do if I have this product?

Voluntary: Firm initiated · Telephone